A PRELIMINARY STUDY TO EVALUATE CYSTEAMINE THERAPY IN HUMAN SUBJECTS WITH NASH

评估半胱胺治疗纳什人类受试者的初步研究

• 批准号: 8166857
• 负责人: JOEL Edward LAVINE
• 金额: $ 1.83万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166857
• 关键词: Biological Markers; Computer Retrieval of Information on Scientific Projects Database; Cysteamine; Funding; Grant; Institution; Research; Research Personnel; Resources; Source; Steatohepatitis; United States National Institutes of Health; human subject

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in human subjects.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 确定cysteamine是否会有效地减少或扭转人类受试者中脂肪性肝炎的生物学标志物。